Rebuilding After Sa...
Health Care: Drugs
Dynavax Technologies Corporation (DVAX: NASDAQ)
$2.52 0.01 | 0.40%
05/22/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 9.71M | 21.61M | 23.95M | 40.32M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 9.71M | 21.61M | 23.95M | 40.32M |
| Selling, General, and Administrative Expenses | 28.16M | 17.57M | 16.88M | 15.74M |
| Research & Development | 49.15M | 51.32M | 53.68M | 38.71M |
| Operating Income before D & A (EBITDA) | -67.60M | -47.28M | -46.61M | -14.14M |
| Depreciation & Amortization | 2.50M | 2.77M | 2.76M | 2.84M |
| Interest Income | 291.00K | 103.00K | 85.00K | 112.00K |
| Other Income - Net | -293.00K | 834.00K | -8.15M | -19.67M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -70.10M | -49.12M | -57.44M | -36.53M |
| Interest Expense | 2.35M | 1.96M | 1.65M | 124.00K |
| Pre-Tax Income | -72.45M | -51.07M | -59.09M | -36.66M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | -4.23M |
| Net Income From Continuing Operations | -69.95M | 0.00 | 0.00 | -30.56M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -69.95M | 0.00 | 0.00 | -30.56M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -69.95M | -48.60M | -57.31M | -30.56M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-69.95M | 0.00 | 0.00 | -30.56M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -69.95M | 0.00 | 0.00 | -30.56M |
| Basic EPS from Continuing Ops. | -0.41 | -0.39 | -0.69 | -0.76 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.41 | -0.39 | -0.69 | -0.76 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.41 | -0.39 | -0.69 | -0.76 |
| Basic Normalized Net Income/Share | -0.41 | n.a. | n.a. | -0.76 |
| EPS fr Continuing Ops. | -0.41 | -0.39 | -0.69 | -0.76 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.41 | -0.39 | -0.69 | -0.76 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.41 | -0.39 | -0.69 | -0.76 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.41 | n.a. | n.a. | -0.76 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DVAX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Usercdm1
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
- Contributor10 Stocks Boosting Little F...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks of Top-Performing...
Latest DVAX Headlines from TheStreet
- 5 Stocks Under $5 to Watch 03.13.13 | 07:03 am
- Stocks Waver as Investors Eye Italian Election 02.25.13 | 02:02 pm
- Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection 02.25.13 | 07:02 am
- Stock Futures Point to Higher Open 02.25.13 | 07:02 am
- Run-Up Trade Into Dynavax's FDA Approval Decision 02.13.13 | 07:02 am
- Dynavax Options Trade For Heplisav FDA Approval Decision 02.12.13 | 08:02 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- 'Mad Money' Lightning Round: I'm Avoiding Controversial Coinstar 02.07.13 | 06:02 am
- Cramer's 'Mad Money' Recap: Pay Attention 02.06.13 | 07:02 pm
Press Releases for DVAX
Partner Headlines for DVAX
- Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine Development - Seeking Alpha 11.21.12 | 09:11 am
- Mid-Day Markets Update: Markets Recover on Fiscal Cliff Meeting; Casino Stocks Continue to Ramp - Benzinga 11.16.12 | 01:11 pm
- Dynavax Gets Crushed After Advisory Committee Vote - Seeking Alpha 11.16.12 | 09:11 am
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (9/14/12) - Seeking Alpha 09.16.12 | 06:09 am
- 3 Vaccine Companies With Upcoming Catalysts - Seeking Alpha 09.09.12 | 08:09 am
- Company News for May 10, 2012 - Corporate Summary - Zacks 05.10.12 | 10:05 am
- Buy And Sell Ideas Based On Monday's Big Biotech News Movers - Seeking Alpha 10.11.11 | 08:10 am
- Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial - Benzinga 10.06.11 | 04:10 pm
- 7 Breakout Stocks With Sufficient Cash to Cover Operating Expenses - Seeking Alpha 03.29.11 | 08:03 am
- Data from Dynavax for HBV Candidate - Analyst Blog - Zacks 12.27.10 | 01:12 pm
